High-sensitivity cardiac troponin I assays, when considered in the context of appropriate thresholds, can identify and expedite triage of patients at varying levels of risk for myocardial infarction, a JACC study found.

Massachusetts-based Azurity Pharmaceuticals announced July 10 it had received FDA approval for Katerzia Oral Suspension, making the drug the first and only FDA-approved amlodipine oral suspension to hit the commercial market.

A study of more than a quarter of a million heart patients in Canada has revealed statins are “significantly” underutilized to treat lipid abnormalities in individuals with and at risk for ASCVD.

A JACC: Cardiovascular Interventions study published this month suggests machine learning models are more predictive and discriminative than standard methods for identifying patients at the greatest risk of CV mortality and rehospitalization after PCI.

Methamphetamine abuse is on the rise among veterans with concomitant heart failure, according to a recent analysis published in the American Journal of Cardiology. 

A federal judge has set a 10-month deadline, ending in May 2020, for e-cigarette and cigar makers to apply for FDA authorization to keep their products on the market.

Abbott’s fourth-generation MitraClip device was approved by the FDA July 15 to treat mitral regurgitation (MR) in a wider population of patients, the company announced this week.

Heavy air pollution in China could be contributing to a greater instance of coronary atherosclerosis among the country’s general population, according to research out of the University of Buffalo.